http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
PureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol (CBD) Leveraging PureTech’s Glyph™ Platform
-
PureTech to Present at Two Upcoming Investor Conferences
-
PureTech to Present at the Jefferies London Healthcare Conference
-
PureTech to Present at the Credit Suisse 31st Annual Healthcare Conference
-
PureTech to Present at the Morgan Stanley Global Healthcare Conference
-
PureTech Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022
-
PureTech Health plc – Half-Year Report
-
PureTech Founded Entity Sonde Health Announces Multi-Year Partnership with Koye Pharmaceuticals
-
PureTech Health: Notice of Half-Yearly Results
-
PureTech Health's (PRTC) Akili Announces Phase 3 Study of Digital Treatment in Children with ADHD Begun by Shionogi in Japan
-
PureTech Founded Entity Akili Announces Phase 3 Study of Digital Treatment in Children with ADHD Begun by Shionogi in Japan
-
PureTech Health's (PRTC) Akili Announces Publication Demonstrating Improved Executive Function in Patients with Systemic Lupus Erythematosus Following Use of AKL-T01 Product Candidate
-
PureTech Founded Entity Akili Announces the Journal Lupus Publishes Investigator-Initiated Study Results Demonstrating Improved Executive Function in Patients with Systemic Lupus Erythematosus Followi
-
PureTech Founded Entity Akili Announces Public Company Board of Director Nominees
-
PureTech Initiates Late-Stage Clinical Study of Wholly-Owned Candidate LYT-100 (Deupirfenidone) in IPF and Advances LYT-200 (Anti-Galectin-9 mAb)
-
PureTech Founded Entity Vedanta Biosciences Unveils State-of-the-Art Manufacturing Facility to Provide Clinical and Commercial Supply of Oral Therapies Based on Defined Bacterial Consortia
-
Results of Annual General Meeting
-
PureTech Health Plc (PRTC) Announces Phase 2 Results of LYT-100-COV in Post-Acute 'Long' COVID
-
PureTech Meets Milestone of Achieving Oral Bioavailability of Allopregnanolone in Healthy Adults Dosed with LYT-300
-
PureTech Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute “Long” COVID with Respiratory Complications
-
PureTech Health Plc (PRTC) Announces Akili Appoints Matt Franklin as President and COO
-
PureTech Founded Entity Akili Announces Veteran Life Sciences Executive Matt Franklin in Newly Created Role of President and Chief Operating Officer
-
PureTech to Present at the Jefferies Healthcare Conference
-
PureTech Health's (PRTC) Akili Integrates Prescription Video Game Treatment with the Virtual World Through Partnership with Roblox
-
PureTech Founded Entity Akili Integrates First-of-its-Kind Prescription Video Game Treatment with the Virtual World Through Partnership with Roblox
-
PureTech's (PRTC) Vedanta Biosciences Presented Data from Multiple Studies
-
PureTech Founded Entity Vedanta Biosciences Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting
-
PureTech to Present at the UBS Global Healthcare Conference
-
PureTech (PRTC) Presents Additional Phase 1 Data for LYT-100
-
PureTech Presents Additional Phase 1 Data for LYT-100 at American Thoracic Society 2022
-
PureTech Announces Share Buyback Program Update
-
PureTech Health Plc (PRTC) Announces $50M Share Buyback
-
PureTech Announces Share Buyback Program of up to $50 Million
-
PureTech Founded Entity Gelesis Announces Clinical Data Demonstrating Weight Loss with GS200 in Adults with Prediabetes and Type 2 Diabetes Presented at the European Congress on Obesity 2022
-
PureTech Founded Entity Gelesis Announces its Proprietary Superabsorbent Hydrogel Induced Beneficial Changes to the Gut Microbiota and Expanded Akkermansia, a Bacterial Species Associated with Gut Hea
-
PureTech Announces Annual Results for Year Ended December 31, 2021
-
PureTech's (PRTC) Founded Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303
-
PureTech Founded Entity Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303 in Cell Host & Microbe and Highlights Planned Presentations of Phase 2 VE303 Results
-
PureTech Health-Founded (PRTC) Akili Interactive Reports Publication of Data Demonstrating its Digital Therapeutic AKL-T03 Improves Cognitive Impairments in Adults w/ Major Depressive Disorder When Co
-
PureTech Founded Entity Akili Announces American Journal of Psychiatry Publication of Data Demonstrating its Digital Therapeutic AKL-T03 Improves Cognitive Impairments in Adults w/ Major Depressive Di
-
PureTech Health (PRTC) Announces Publication from Collaborators Demonstrating PureTech’s Glyph Platform Enhances Oral Absorption of Buprenorphine
-
PureTech Announces Publication of Research from Collaborators Demonstrating PureTech’s Glyph™ Platform Enhances Oral Absorption of Buprenorphine (a Clinically-Validated Opioid Replacement Therapy)
-
PureTech Health: Notice of Results
-
PureTech Appoints Sharon Barber-Lui to Board of Directors & Audit Committee
-
PureTech Health's (PRTC) Akili Appoints Jon David as Chief Product Officer
-
PureTech Founded Entity Akili Appoints Game Industry Veteran Behind Bejeweled, Plants vs. Zombies as Chief Product Officer
-
PureTech Health's (PRTC) Gelesis Holdings (GLS) Reports Record Preliminary National Launch Results for Plenity
-
PureTech Founded Entity Gelesis® Releases Preliminary National Launch Results for Plenity®: Record-Breaking Levels of Prescriptions and Online Traffic
-
PureTech Founded Entity Akili Named to Fast Company’s Annual List of the World’s 50 Most Innovative Companies for 2022
-
PureTech Founded Entity Akili Announces PLOS ONE Publication of Clinical Study Results and EEG Data Showing Akili Digital Therapeutic EndeavorRx® Activates Systems in Brain Key to Attentional Functio

